What it’s for
- Erectile dysfunction and selected urinary or pulmonary conditions
A prescription medicine that inhibits PDE5.
Purpose, evidence and practical considerations.
Evidence supports specific indications and dosing regimens. Improvement in erectile function does not establish general cardiovascular protection or longer life.
Confidence: strong
Tadalafil must not be combined with nitrates or riociguat because of dangerous hypotension. Headache, flushing, dyspepsia, nasal congestion, back pain and dizziness are common; sudden vision or hearing loss and priapism require urgent care. Cardiovascular fitness for sexual activity, alpha-blockers, kidney or liver disease and CYP3A interactions require prescriber review.
Tadalafil inhibits phosphodiesterase type 5, preserving nitric-oxide-mediated cGMP signalling in smooth muscle. This supports erections with sexual stimulation and improves lower urinary tract symptoms in benign prostatic hyperplasia; surrogate endothelial effects do not establish cardiovascular prevention or longevity.
Regulatory status: Prescription-only in the United States, European Union, UK, Canada, and Australia. Not a controlled substance in the US. EMA-authorized Cialis and Adcirca plus generics. Absolute contraindications on current US labeling: any organic nitrate (regular or intermittent); serious hypersensitivity to tadalafil; guanylate-cyclase stimulators (riociguat).
How people use it, with their schedules, context and original sources.
5 mg · Daily
endothelial function, inflammation, nighttime erections
Dose and schedule patterns reported in public protocols; these are observations, not prescribing advice. Private and hidden usage is excluded.
daily
These share a protocol with this intervention. This does not establish that they work together or are suitable alternatives.